Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Pathophysiology and Preclinical Endpoints of Retinopathy in a Murine Model of Zellweger Spectrum Disorder
FY 2020-21
Summary
Peroxisomes are ubiquitous sub-cellular structures and are required for many vital metabolic processes. Zellweger Spectrum Disorder (ZSD) is a genetic disease in which peroxisome formation and function is impaired. ZSD patients suffer from progressive retinopathy leading to vision loss, impacting their quality of life. Our laboratory developed a mouse model with a genetic mutation in the PEX1 gene, equivalent to the most common ZSD-causing mutation in humans. Despite having dramatically reduced retinal function and visual acuity, retinal cell structure is relatively well preserved in these mice. This suggests that peroxisome dysfunction affects retinal cell function more than structure, but the mechanism(s) for this remain(s) unknown. I aim to study the pathophysiology of ZSD using our mouse model to define the mechanism by which peroxisome dysfunction leads to retinopathy. I hypothesize that by assessing the retina electrophysiological and histological response to various functional challenges, I can elucidate how PEX1 deficiency disrupts retinal function. The experiments I will complete have never been performed on any peroxisome deficient animal model, and will provide a more in-depth understanding of the role of peroxisomes in retinal health. This work will define which cell types and retinal processes are most affected by peroxisome dysfunction, thereby identifying therapeutic targets for ZSD and other peroxisome-mediated vision loss. Currently, our lab is developing gene and drug-based therapies to improve vision in ZSD. My studies will complement these efforts by ensuring the correct cell types are targeted, and identifying additional electrophysiological outcome measures to assess functional retinal improvement in response to therapy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449408
Name
Smolash Kelsey
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Pathophysiology and Preclinical Endpoints of Retinopathy in a Murine Model of Zellweger Spectrum Disorder
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Genetic Disease; Metabolic Disease; Pathophysiology; Peroxisome Biogenesis Disorder; Retinopathy; Vision; Zellweger Spectrum Disorder
Abstract
Peroxisomes are ubiquitous sub-cellular structures and are required for many vital metabolic processes. Zellweger Spectrum Disorder (ZSD) is a genetic disease in which peroxisome formation and function is impaired. ZSD patients suffer from progressive retinopathy leading to vision loss, impacting their quality of life. Our laboratory developed a mouse model with a genetic mutation in the PEX1 gene, equivalent to the most common ZSD-causing mutation in humans. Despite having dramatically reduced retinal function and visual acuity, retinal cell structure is relatively well preserved in these mice. This suggests that peroxisome dysfunction affects retinal cell function more than structure, but the mechanism(s) for this remain(s) unknown. I aim to study the pathophysiology of ZSD using our mouse model to define the mechanism by which peroxisome dysfunction leads to retinopathy. I hypothesize that by assessing the retina electrophysiological and histological response to various functional challenges, I can elucidate how PEX1 deficiency disrupts retinal function. The experiments I will complete have never been performed on any peroxisome deficient animal model, and will provide a more in-depth understanding of the role of peroxisomes in retinal health. This work will define which cell types and retinal processes are most affected by peroxisome dysfunction, thereby identifying therapeutic targets for ZSD and other peroxisome-mediated vision loss. Currently, our lab is developing gene and drug-based therapies to improve vision in ZSD. My studies will complement these efforts by ensuring the correct cell types are targeted, and identifying additional electrophysiological outcome measures to assess functional retinal improvement in response to therapy.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Smolash, Kelsey
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~